よむ、つかう、まなぶ。

MC plus(エムシープラス)は、診療報酬・介護報酬改定関連のニュース、

資料、研修などをパッケージした総合メディアです。


【資料No.1】2.5_臨床に関する概括資料 (160 ページ)

公開元URL https://www.mhlw.go.jp/stf/newpage_29325.html
出典情報 薬事・食品衛生審議会 薬事分科会(令和4年度第5回 11/22)、医薬品第二部会(令和4年度第13回 11/22)(合同開催)《厚生労働省》
低解像度画像をダウンロード

資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。

S-217622

表 2.5.5.1-8

2.5 臨床に関する概括評価

有害事象発現状況の概要:Phase 2b Part (安全性解析対象集団)
S-217622
125 mg
N = 140

S-217622
250 mg
N = 140

N = 141

48
(64)
34.3
[26.5, 42.8]

60
(89)
42.9
[34.5, 51.5]

44
(53)
31.2
[23.7, 39.5]

TEAEs with an outcome of death
- Number of participants
- (Number of events)
- Percentage of participants (%)
- 95% Confidence interval (%)

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

Serious TEAEs other than deaths
- Number of participants
- (Number of events)
- Percentage of participants (%)
- 95% Confidence interval (%)

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

2
(2)
1.4
[0.2, 5.0]

Treatment-emergent adverse events
- Number of participants
- (Number of events)
- Percentage of participants (%)
- 95% Confidence interval (%)

Placebo

TEAEs leading to discontinuation of study
intervention
- Number of participants
2
0
0
- (Number of events)
(3)
(0)
(0)
- Percentage of participants (%)
1.4
0.0
0.0
- 95% Confidence interval (%)
[0.2, 5.1]
[0.0, 2.6]
[0.0, 2.6]
TEAE = Treatment-emergent Adverse Event
Treatment-emergent adverse events were defined as any AE reported after the first dose of the study intervention.
The confidence intervals were calculated by using Clopper-Pearson method.
出典:5.3.5.1-01_T1221 CSR (Phase 2b Part)_Table 14.3.1.1.1.1.1-2

表 2.5.5.1-9

副作用発現状況の概要:Phase 2b Part (安全性解析対象集団)
S-217622
125 mg
N = 140

S-217622
250 mg
N = 140

N = 141

Treatment-related TEAEs
- Number of participants
- (Number of events)
- Percentage of participants (%)
- 95% Confidence interval (%)

19
(24)
13.6
[8.4, 20.4]

31
(38)
22.1
[15.6, 29.9]

7
(7)
5.0
[2.0, 10.0]

Treatment-related TEAEs with an outcome of death
- Number of participants
- (Number of events)
- Percentage of participants (%)
- 95% Confidence interval (%)

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

Serious Treatment-related TEAEs other than deaths
- Number of participants
- (Number of events)
- Percentage of participants (%)
- 95% Confidence interval (%)

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

0
(0)
0.0
[0.0, 2.6]

Treatment-related TEAEs leading to discontinuation
of study intervention

- 160 -

Placebo